Safety and efficacy study in patients with moderate to severe nail psoriasis

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005413-40

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe psoriasis affecting the nails as assessed by NAPSI at Week 16


Critère d'inclusion

  • Moderate to severe nail psoriasis